HUTCHMED (HCM) said late Wednesday that China's National Medical Products Administration has granted breakthrough therapy designation to Orpathys in combination with Tagrisso to treat non-small cell lung cancer patients.
The designation qualifies the treatment candidate for a potential conditional approval and priority review, the company said.
The drug cocktail is currently being evaluated in a phase 3 trial in China.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。